Tremelimumab 生物類似藥, 人 CTLA-4 單克隆抗體-Tremelimumab Biosimilar, Human CTLA-4 monoclonal antibody代理/參數/廠家-二抗-艾美捷科技有限公司

PRODUCT CENTER

二抗

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > 二抗

背景資料: What is Tremelimumab biosimilar research grade? Tremelimumab (formerly ticilimumab) is a fully human monoclonal antibody against CTLA-4 / CD152. It is an immune checkpoint blocker. Unlike Ipilimumab (another fully human anti-CTLA-4 / CD152 monoclonal antibody), which is an IgG1 isotype, tremelimumab is an IgG2 isotype.Tremelimumab Biosimilar uses the same protein sequences as the therapeutic antibody tremelimumab.nnTremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. This is immune checkpoint blockade.nnTremelimumab binds to the protein CTLA-4 / CD152, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4 / CD152, resulting in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation; subsequently, B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition.

保存建議: Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

其他: ProMab 生物技術公司通過整合生物信息學、分子生物學、蛋白質表達、純化技術、基因克隆、微生物學和免疫學，利用新型高通量技術開發重組蛋白、抗體和工程細胞系并將其商業化。專注于免疫治療領域，特別是 CAR-T/NK 細胞技術。ProMab 還開發了一種新型的 mRNA 脂質納米顆粒（mRNA-LNP）平臺，用于即用型試劑和定制研究服務，以推進現有產品并擴展到更多的研究領域。